Cargando…

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks

INTRODUCTION: The Apixaban for the Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY), and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deitelzweig, Steve, Amin, Alpesh, Jing, Yonghua, Makenbaeva, Dinara, Wiederkehr, Daniel, Lin, Jay, Graham, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107424/ https://www.ncbi.nlm.nih.gov/pubmed/25135394 http://dx.doi.org/10.1007/s40119-013-0020-5

Ejemplares similares

Health Care Burden of Dyspepsia Among Nonvalvular Atrial Fibrillation Patients
por: Kim, Michael H., et al.
Publicado: (2014)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits
por: Amin, Alpesh, et al.
Publicado: (2015)

Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies
por: Amin, Alpesh
Publicado: (2013)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
por: Deitelzweig, Steve, et al.
Publicado: (2018)

Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation
por: Boivin-Proulx, Laurie-Anne, et al.
Publicado: (2022)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis
por: Mendoza-Sanchez, Jose, et al.
Publicado: (2018)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Elfar, Sohil, et al.
Publicado: (2022)

Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study
por: Bah, Aissa, et al.
Publicado: (2021)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population
por: Amin, Alpesh, et al.
Publicado: (2019)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study
por: Calkins, Hugh, et al.
Publicado: (2019)

Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach?
por: Brunetti, Natale Daniele, et al.
Publicado: (2020)

Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation
por: Akhtar, Tauseef, et al.
Publicado: (2020)

A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
por: Stambler, Bruce S
Publicado: (2013)

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
por: Hammwöhner, Matthias, et al.
Publicado: (2020)

Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study
por: Hong, Keun-Sik, et al.
Publicado: (2017)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair
por: Mentias, Amgad, et al.
Publicado: (2022)

Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
por: Pyykönen, Mikko, et al.
Publicado: (2021)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid‐range, and reduced left ventricular ejection fraction
por: Wu, Victor Chien‐Chia, et al.
Publicado: (2020)

Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry
por: Sciria, Christopher T., et al.
Publicado: (2020)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
por: Liu, Xuyang, et al.
Publicado: (2022)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Stability of High‐Quality Warfarin Anticoagulation in a Community‐Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
por: Dallalzadeh, Liane O., et al.
Publicado: (2016)

Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management
por: Bahbahani, Hamad, et al.
Publicado: (2018)

Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States
por: Deitelzweig, Steven, et al.
Publicado: (2020)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation
por: Galea, Roberto, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fnvssu8gnkv3tou11df296ec9i